These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9027536)

  • 21. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants.
    Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL
    JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemophilus influenzae type B conjugate vaccines.
    Force RW; Lugo RA; Nahata MC
    Ann Pharmacother; 1992 Nov; 26(11):1429-40. PubMed ID: 1477450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP).
    MMWR Recomm Rep; 1991 Jan; 40(RR-1):1-7. PubMed ID: 1899280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
    Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
    Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measuring the impact of conjugate vaccines on invasive Haemophilus influenzae type b infection in Western Australia.
    Bower C; Condon R; Payne J; Burton P; Watson C; Wild B
    Aust N Z J Public Health; 1998 Feb; 22(1):67-72. PubMed ID: 9599855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group.
    Wenger JD; Pierce R; Deaver KA; Plikaytis BD; Facklam RR; Broome CV
    Lancet; 1991 Aug; 338(8764):395-8. PubMed ID: 1678080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of Haemophilus influenzae B-diphtheria conjugate vaccination in German children].
    Zielen S; Scheurer J; Rhodius U; Schäfer V; Isenberg H; Bauscher P; Schröder S; Ahrens P; Hofmann D
    Monatsschr Kinderheilkd; 1992 Dec; 140(12):852-6. PubMed ID: 1491705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vaccine against Haemophilus influenzae type b--antibody response and adverse effects].
    Nøkleby H; Sandbu S; Käyhty H; Olander RM; Heilmann C
    Tidsskr Nor Laegeforen; 1995 May; 115(13):1604-6. PubMed ID: 7778073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
    Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
    Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.
    Monge S; Hahné SJ; de Melker HE; Sanders EA; van der Ende A; Knol MJ
    Lancet Infect Dis; 2018 Jul; 18(7):749-757. PubMed ID: 29752131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of a Haemophilus influenzae type b-tetanus conjugate vaccine when administered separately or in combined vaccines for primary immunization in two consecutive national schedules in Turkey.
    Yüksel N; Beyazova U; Balci IF; Aksakal FN; Camurdan AD; Sahin F; Rota S
    Int J Infect Dis; 2012 May; 16(5):e354-7. PubMed ID: 22387144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression, avidity, and vaccine formulation. The Collaborative Vaccine Study Group.
    Granoff DM; Shackelford PG; Holmes SJ; Lucas AH
    J Clin Invest; 1993 Mar; 91(3):788-96. PubMed ID: 8450060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine.
    Murphy TV; Pastor P; Medley F; Osterholm MT; Granoff DM
    J Pediatr; 1993 Apr; 122(4):517-23. PubMed ID: 8463894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use.
    Black SB; Shinefield HR; Fireman B; Hiatt R
    J Infect Dis; 1992 Jun; 165 Suppl 1():S139-43. PubMed ID: 1588149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Need for prevention of invasive Haemophilus influenzae type b infections in Geneva, Switzerland.
    Gervaix A; Suter S
    Vaccine; 1993; 11 Suppl 1():S34-7. PubMed ID: 8447172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children.
    Takala AK; Santosham M; Almeido-Hill J; Wolff M; Newcomer W; Reid R; Käyhty H; Esko E; Mäkelä PH
    Pediatr Infect Dis J; 1993 Jul; 12(7):593-9. PubMed ID: 8346004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group.
    Vadheim CM; Greenberg DP; Eriksen E; Hemenway L; Bendana N; Mascola L; Ward JI
    Arch Pediatr Adolesc Med; 1994 Jan; 148(1):51-6. PubMed ID: 8143010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.